Navigation Links
Watson Pharmaceuticals Receives FDA Final Approval for Generic Mircette(R)
Date:12/29/2008

CORONA, Calif., Dec. 29 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI), a leader in generic and specialty branded pharmaceuticals, today announced that its subsidiary, Watson Laboratories, Inc., has received final approval from the United States Food and Drug Administration on its Abbreviated New Drug Application (ANDA) for desogestrel/ethinyl estradiol and ethinyl estradiol tablets USP, 0.15 mg / 0.02 mg. Desogestrel/ethinyl estradiol and ethinyl estradiol tablets, USP, is the generic equivalent to Duramed Pharmaceuticals' Mircette(R) low-dose monthly oral contraceptive product, which is indicated for prevention of pregnancy.

Watson intends to launch the product in early January 2009 under the trade name Azurette(TM). For the 12-months ending September 2008, Mircette(R) had total U.S. sales of approximately $135 million, according to IMS Health data.

About Watson Pharmaceuticals, Inc.

Watson Pharmaceuticals, Inc. is a leading specialty pharmaceutical company that develops, manufactures, markets, sells and distributes generic and specialty brand pharmaceutical products. Watson pursues a growth strategy combining internal product development, strategic alliances and collaborations and synergistic acquisitions of products and businesses. For press releases and other company information, visit Watson Pharmaceuticals' Web site at http://www.watson.com.

Forward-Looking Statement

Any statements contained in this press release that refer to future events or other non-historical facts are forward-looking statements that reflect Watson's current perspective of existing trends and information as of the date of this release. Except as expressly required by law, Watson disclaims any intent or obligation to update these forward-looking statements. Actual results may differ materially from Watson's current expectations depending upon a number of factors affecting Watson's business. These factors include, among others, the impact of competitive products and pricing; market acceptance of and continued demand for Watson's products; difficulties or delays in manufacturing; the difficulty of predicting the timing or outcome of FDA or other regulatory agency approvals or actions, if any; patents and other intellectual property rights held by third parties; and other risks and uncertainties detailed in Watson's periodic public filings with the Securities and Exchange Commission, including but not limited to Watson's Annual Report on Form 10-K for the year ended December 31, 2007.

Mircette(R) is a registered trademark of Duramed Pharmaceuticals, Inc.

(Logo: http://www.newscom.com/cgi-bin/prnh/20020214/WATSONLOGO)


'/>"/>
SOURCE Watson Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. U.S. Workers Taking Steps to Lower Medical Costs, Watson Wyatt Survey Finds
2. China Shenghuo Announces Additional Roll-Out of 12 Ways Cosmetics Products to Watsons Stores
3. Driving Consumer Engagement Is Focus of Address by Healthfitness Chief Medical Officer at Watson Wyatt Health Care Solutions Event
4. Watson Pharmaceuticals Receives FDA Final Approval for Generic Wellbutrin XL(R) 150 mg
5. Watson Enters Into Agreement to Acquire Products Related to Tevas Proposed Acquisition of Barr
6. Watson Announces the NDA for a 6-Month Formulation of TRELSTAR(R) Accepted for Filing by FDA for the Treatment of Advanced Prostate Cancer
7. Watson Pharmaceuticals Reports Third Quarter 2008 Results
8. Watson Receives US FDA Approval for RAPAFLO(TM) (silodosin) for the Treatment of Benign Prostatic Hyperplasia (BPH)
9. Older Workers Worried About Promised Medicare and Social Security Benefits, Watson Wyatt Survey Finds
10. Watson Wyatt Identifies Trends for Benefits Open Enrollment Season
11. Watson Announces District Court Ruling in Naproxen Sodium Patent Suit
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... ... March 28, 2017 , ... Thank you to all who attended Capio ... , This event was exclusive to providers and offered an opportunity to collaborate and ... at the Manchester Grand Hyatt where attendees gathered for a lively discussion on trends ...
(Date:3/28/2017)... , ... March 28, 2017 , ... “A Prophets Bones”: a thrilling adventure that reveals ... Quinn. , “There were things that his parents and teachers had asked of him that ... that he was going to defy the Almighty Creator. There were some who would have ...
(Date:3/27/2017)... ... March 27, 2017 , ... New patients who have sleep ... apnea treatment, with or without a referral. Sleep apnea is often left untreated because ... sleepiness, morning headaches and chronic snoring. , Dr. Braasch seeks to raise awareness ...
(Date:3/27/2017)... Claire, WI (PRWEB) , ... March 27, 2017 ... ... accepting new patients for custom smile makeovers without requiring a referral. ... including orthodontics, gum disease treatment, cosmetic dentistry and dental implants. Whether patients have ...
(Date:3/27/2017)... ... 2017 , ... Drs. Justin Kolnick, Kara Diamond, Randall Barton, Keith Hope and ... key role this treatment plays in protecting oral health, along with the benefits of ... who need a root canal in White Plains, NY or their second location in ...
Breaking Medicine News(10 mins):
(Date:3/27/2017)... CHICAGO , March 27, 2017  A ... Educators (AADE) found that Medicare,s Competitive Bidding Program (CBP) ... diabetes testing supplies. The lack of choice forces beneficiaries ... can have dire health consequences. AADE,s ... reports by AADE and others pointing out the inherent ...
(Date:3/27/2017)... 2017 FinancialBuzz.com News Commentary  ... Based on New Frontier Data,s sales ... cannabis is legal will generate $655 million in taxes on retail ... specific taxes, such as Washington State,s 37% ... from state sales taxes that are applied on all retail sales. ...
(Date:3/27/2017)... , March 27, 2017 BioLineRx Ltd. ... immunology, announced today that AGI-134, an immunotherapy for the treatment ... Agalimmune Ltd., will be featured at the upcoming American ... Washington, DC to be held on April ... ...
Breaking Medicine Technology: